Metformin induces weight loss associated with gut microbiota alteration in non-diabetic obese women: a randomized double-blind clinical trial
Abstract
OBJECTIVE
The increasing prevalence of obesity over the past few decades constitutes a global health challenge. Pharmacological therapy is recommended to accompany life-style modification for obesity management. Here, we perform a clinical trial to investigate the effects of metformin on anthropometric indices and gut microbiota composition in non-diabetic, treatment-naive obese women with a low calorie diet (LCD).
DESIGN
Randomized double-blind parallel-group clinical trial Methods: Forty-six obese women were randomly assigned to the metformin (500 mg/tab) or placebo groups using computer-generated random numbers. Subjects in both groups took two tablets per day for two months. Anthropometric measurements and collection of blood and faecal samples were done at the baseline and at the end of the trial. Gut microbiota composition was assessed using 16S rRNA amplicon sequencing.
RESULTS
Twenty-four and twenty-two subjects were included in the metformin+LCD and placebo+LCD groups, respectively; at the end of trial twenty and sixteen subjects were analyzed. The metformin+LCD and placebo+LCD caused a 4.5% and 2.6% decrease in BMI from the baseline values, respectively (P<0.01). Insulin concentration decreased in the metformin+LCD group (P=0.046). The overall faecal microbiota composition and diversity were unaffected in the metformin+LCD group. However, a significant specific increase in Escherichia/Shigella abundance was observed after metformin+LCD intervention (P=0.026).…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.